February 5, 2010
Strativa Pharmaceuticals Provides An Update On Zuplenz®(ondansetron) Oral Soluble Film
February 2, 2010
Par Pharmaceutical Companies To Report Fourth Quarter And Full Year 2009 Results On February 24, 2010
November 25, 2009
Par Pharmaceutical Announces Results of its “Modified Dutch Auction” Tender Offer
November 16, 2009
Par Pharmaceutical To Host Analyst Day On December 3rd
Par Pharmaceutical Receives Final Approval To Market Generic Ultram® ER
November 09, 2009
Par Pharmaceutical Announces Extension and Increase in Maximum Purchase Price for "Modified Dutch Auction" Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
November 06, 2009
Par Pharmaceutical Reports EPS Of $0.76 For Third Quarter 2009
October 22, 2009
Par Pharmaceutical To Host Third Quarter 2009 Earnings Conference Call On November 6 At 9:00 AM
October 14, 2009
Par Pharmaceutical Announces “Modified Dutch Auction” Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
September 14, 2009
Strativa Pharmaceuticals’ Development Partner, Bioalliance Pharma, Presents Phase III Study Results Of Miconazole Lauriad® For The Treatment Of Oropharyngeal Candidiasis
September 10, 2009
Par Pharmaceutical Receives Final Approval To Market Generic Starlix®
August 19, 2009
FDA Accepts Drug Application For Miconazole Lauriad® To Treat Oropharyngeal Candidiasis
August 18, 2009
Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval To Market Generic Catapres TTS®
August 17, 2009
Par Pharmaceutical Wins On Invalidity In Ultram® ER Litigation
August 4, 2009
Par Pharmaceutical Reports EPS Of $0.71 For Second Quarter 2009
July 15, 2009
Par Pharmaceutical To Host Second Quarter 2009 Earnings Conference Call On August 4 At 9:00 AM
June 16, 2009
Strativa’s Development Partner, Bioalliance Pharma, Submits Loramyc® NDA
June 12, 2009
Thomas P. Rice Elected To Board Of Directors Of Par Pharmaceutical Companies, Inc.
June 10, 2009
Strativa’s New Drug Application For Ondansetron Orally Dissolving Film Strip Accepted By FDA
June 9, 2009
Par Pharmaceutical Begins Shipment Of Generic Miacalcin®
June 2, 2009
Par Pharmaceutical Begins Shipment Of Generic Risperdal® M-TAB
May 6, 2009
Par Pharmaceutical Reports Adjusted EPS Of $0.49 For First Quarter 2009
April 29, 2009
Par Pharmaceutical To Host First Quarter 2009 Earnings Conference Call On May 6 At 9:00 AM
April 21, 2009
Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals To Settle Patent Litigation Over Rythmol® SR
April 9, 2009
Strativa Pharmaceuticals Provides Product Pipeline Update
April 1, 2009
Strativa Pharmaceuticals Acquires Worldwide Rights To Nascobal® (Cyanocobalamin, USP) Nasal Spray From QOL Medical
March 2, 2009
Par Pharmaceutical Reports Fourth Quarter And Full Year 2008 Results
February 25, 2009
Par Pharmaceutical To Host Fourth Quarter And Full Year 2008 Results Conference Call On March 3 At 9:00 AM
February 10, 2009
Par Pharmaceutical Announces Outcome Of The Litigation With Pentech Pharmaceuticals
February 2, 2009
Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved Androgel® Litigation Settlement
January 7, 2009
Par Pharmaceutical To Present At The 27th Annual J.P. Morgan Healthcare Conference
December 12, 2008
Par Pharmaceutical Announces The Resignation Of Its Chief Financial Officer
December 02, 2008
Strativa Pharmaceuticals Announces Successful Completion Of Bioequivalence Studies For Ondansetron Thin Film
November 20, 2008
Par Pharmaceutical Halts Shipment Of Budesonide Inhalation Suspension
November 19, 2008
Par Pharmaceutical Begins Shipment Of Budesonide Inhalation Suspension Immediately
November 06, 2008
Par Pharmaceutical Reports Third Quarter 2008 Results
Par Pharmaceutical Begins Shipment Of Sumatriptan Injection
October 28, 2008
Par Pharmaceutical To Host Third Quarter 2008 Results Conference Call On November 7 At 9:00 AM
October 14, 2008
Par Pharmaceutical Announces Resizing Of Generic Unit To Optimize Strong First-To-File Pipeline
Gerard A. Martino Resigns As Chief Operating Officer
August 07, 2008
Par Pharmaceutical Reports Second Quarter 2008 Results
July 29, 2008
Par Pharmaceutical To Host Second Quarter 2008 Results Conference Call On August 8 At 9:00 AM
June 30, 2008
Par Pharmaceutical Receives Final Approval To Market Generic Marinol® C-III (Dronabinol) Capsules
June 17, 2008
Strativa Pharmaceuticals Acquires Commercialization Rights To Thin Film Formulation Of Ondansetron From Monosol Rx
May 29, 2008
Strativa Pharmaceuticals Announces Preliminary Results From Onconase® Phase IIIb Clinical Trial
May 08, 2008
Par Pharmaceutical Reports First Quarter 2008 Results
May 07, 2008
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
May 05, 2008
Par Pharmaceutical To Host First Quarter 2008 Earnings Conference Call On May 9 At 9:00 AM
April 21, 2008
Strativa Pharmaceuticals Announces Phase III Results For Loramyc® To Treat Oropharyngeal Candidiasis
February 29, 2008
Par Pharmaceutical Reports Fourth Quarter And Full Year 2007 Results
February 25, 2008
Strativa Pharmaceuticals, A Division Of Par Pharmaceutical, Announces The Discontinuation Of The Development Program For Pafuramidine
January 15, 2008
Strativa Pharmaceuticals Acquires Commercialization Rights
To Onconase® From Alfacell Corporation
December 28, 2007
Strativa Provides an Update on Development Status of In-licensed Products
December 20, 2007
Par Pharmaceutical Reports Third-Quater 2007 Results
November 21, 2007
Par Pharmaceutical Files Form 10-Qs for First and Second Quarters of 2007
October 15, 2007
Par Pharmaceutical Enters into Agreement with Valeant Pharmaceuticals to Settle Patent Litigation over Diastat® and Diastat® AccuDial™
September 28, 2007
Par Pharmaceutical Provides Summary of Analyst/Investor Day
September 24, 2007
Par Invites Public to Listen to Webcast of its September 28 Analysts’ Meeting
September 06, 2007
Par Pharmaceutical Files Form 10-K for 2006
August 09, 2007
Patrick G. LePore Elected Chairman of Board of Directors, Joseph E. Smith Named Lead Director of Par Pharmaceutical Companies, Inc.
August 03, 2007
Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic Toprol-XL®
August 02, 2007
Par Pharmaceutical Announces Equity Investment in Intellipharmaceutics LTD.
August 01, 2007
Par Pharmaceutical Licenses North American Rights to Zensana™ from Hana Biosciences
July 30, 2007
Par Pharmaceutical Files Form 10-Q/A for Third Quarter of 2006
July 26, 2007
Par Pharmaceutical Begins Shipment of Additional Dosage Strengths of Generic Toprol-XL®
July 19, 2007
Par Pharmaceutical Announces Agreement with Ortho-McNeil to Settle Ultracet® Patent Litigation
July 10, 2007
Par Pharmaceutical Files Form 10-Q/As for First and Second Quarters of 2006
July 03, 2007
Par Pharmaceutical Licenses U.S. Commercialization Rights to Loramyc™ From Bioalliance Pharma
June 12, 2007
Par Pharmaceutical Licenses Commercialization Rights to Pafuramidine for Treatment of Pneumocystis Pneumonia
June 07, 2007
Par Pharmaceutical Names Gerard A. Martino EVP and COO, Veronica A. Lubatkin EVP and CFO
May 23, 2007
Par Pharmaceutical to Present at 2007 Friedman Billings Ramsey Growth Conference
April 05, 2007
Par Pharmaceutical to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
March 22, 2007
Par Begins Shipment of Generic Zantac Syrup®
March 13, 2007
Par Pharmaceutical to Present at Lehman Brothers' Tenth Annual Global Healthcare Conference
March 13, 2007
Par Pharmaceutical Files Form 10-K/A with SEC
March 08, 2007
Melvin Sharoky Elected to Board of Directors of Par Pharmaceutical Companies, Inc.™
March 07, 2007
Par Pharmaceutical to Present at Cowen and Company 27th Annual Health Care Conference
March 07, 2007
Par Pharmaceutical Names Paul Campanelli President, Generics Division
February 27, 2007
Par Pharmaceutical Returns Par-101 Marketing Rights to Optimer Pharmaceuticals
January 29, 2007
Par Pharmaceutical Receives Approval of Generic Inderal-LA®
December 26, 2006
Par Pharmaceutical Receives Approval for Ondansetron Orally Disintegrating Tablets
December 14, 2006
Par Pharmaceutical Provides Update on Financial Restatement
November 21, 2006
Par Pharmaceutical Begins Shipment of Generic TOPROL-XL®
November 13, 2006
Par Pharmaceutical Announces Agreement with GlaxoSmithKline to Settle IMITREX® Injection Patent Litigation
November 2, 2006
Par Announces Termination of Cesamet™ Promotion Agreement
October 23, 2006
Par Pharmaceutical Begins Shipment of Pravastatin Tablets
September 26, 2006
Patrick G. LePore Named President and Chief Executive Officer of Par Pharmaceutical Companies, Inc.™
September 13, 2006
Par Pharmaceutical Announces Agreement with Unimed Pharmaceuticals to Settle Androgel® Patent Litigation
September 5, 2006
Par Pharmaceutical to Present at Bear Stearns 19th Annual Healthcare Conference
September 5, 2006
Additional Nanocrystal® Technology Patent Issued Covering Par's Megace® ES
July 19, 2006
Par Pharmaceutical Receives Final Approval to Market Meloxicam Tablets
July 5, 2006
Par Pharmaceutical Will Restate Certain Prior Period Results and Delay Filing its Second Quarter Form 10-Q
June 30, 2006
Par Pharmaceutical Receives Final Approval to Market Tranylcypromine Sulfate Tablets
May 30, 2006
Par Pharmaceutical Receives Final Approval to Market Polyethylene Glycol 3350 for Oral Solution
May 25, 2006
Par Pharmaceutical to Present at 2006 Friedman Billings Ramsey Growth Investor Conference
May 22, 2006
Patrick G. LePore Elected to Board of Directors of Par Pharmaceutical Companies, Inc.™
March 16, 2006
Par Pharmaceutical Names Gerard A. Martino Chief Financial Officer
March 7, 2006
Par Pharmaceutical Resumes Shipment of Generic Flonase®
March 6, 2006
Par Pharmaceutical to Present at Lehman Brothers Ninth Annual Global Healthcare Conference
February 24, 2006
Par Pharmaceutical Halts Shipment of Generic FLONASE®
February 23, 2006
Par Pharmaceutical Announces Product Collaboration with Spectrum Pharmaceuticals, Inc.
February 23, 2006
Par Pharmaceutical Begins Shipment of Generic FLONASE®
January 26, 2006
Par Pharmaceutical Announces Divestiture of FineTech
Archived copies of news releases issued since January 2003 are available on line, grouped by year of release:
|
